

Research Article

MYC, TP53, and Chromosome 17 Copy-Number Alterations in Multiple Gastric Cancer Cell Lines and in Their Parental Primary Tumors

Mariana Ferreira Leal,¹ Danielle Queiroz Calcagno,²
Joana de Fátima Ferreira Borges da Costa,² Tanielly Cristina Raiol Silva,²
André Salim Khayat,² Elizabeth Suchi Chen,¹ Paulo Pimentel Assumpção,³
Marília de Arruda Cardoso Smith,¹ and Rommel Rodríguez Burbano²

¹Genetics Division, Department of Morphology and Genetics, Federal University of São Paulo, 04023-900 São Paulo, SP, Brazil

²Human Cytogenetics Laboratory, Institute of Biological Sciences, Federal University of Pará, 66073-000 Belém, PA, Brazil

³Surgery Service, João de Barros Barreto University Hospital, Federal University of Pará, 60673-000 Belém, PA, Brazil

Correspondence should be addressed to Mariana Ferreira Leal, mariana.morf@epm.br

Received 11 September 2010; Revised 23 December 2010; Accepted 8 January 2011

Academic Editor: Yataro Daigo

Copyright © 2011 Mariana Ferreira Leal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We evaluated whether MYC, TP53, and chromosome 17 copy-number alterations occur in ACP02, ACP03, and AGP01 gastric cancer cell lines and in their tumor counterpart. Fluorescence *in situ* hybridization for MYC and TP53 genes and for chromosome 17 was applied in the 6th, 12th, 60th, and 85th passages of the cell lines and in their parental primary tumors. We observed that three and four MYC signals were the most common alterations in gastric cell lines and tumors. ACP02 presented cells with two copies of chr17 and loss of one copy of TP53 more frequently than ACP03 and AGP01. Only ACP03 and AGP01 presented clonal chr17 trisomy with three or two TP53 copies. The frequency of MYC gain, TP53 loss, and chromosome 17 trisomy seems to increase in gastric cell lines compared to their parental tumors. Our findings reveal that these cell lines retain, *in vitro*, the genetic alterations presented in their parental primary tumors.

1. Introduction

Chromosomal instability is characterized by changes in chromosome copy number (aneuploidy) and alterations in chromosomal regions, which may induce oncogene activation, tumor suppressor gene inactivation, or both. Chromosomal instability is one of the two major genomic instability pathways observed in gastric cancer (GC) [1], the fourth most frequent type of cancer and second most frequent cause of cancer mortality worldwide [2]. However, due to the difficulty in obtaining high-quality chromosome preparations in these neoplasias, the evaluation of chromosomal alterations is complicated [3–7].

Cell lines derived from human cancers are useful in order to understand the chromosomal alterations and other molecular alterations in the carcinogenesis process. Cell lines

are also a useful tool for the study of anticancer treatments *in vitro* and in animal xenograft models. However, the process of cell line immortalization has been implicated as a source of cytogenetic changes, and growth passages have been associated with random genomic instability [8–11]. Given their importance as models, it is important to understand in which way and to what degree cell lines grown under artificial conditions reflect their parental *in vivo* genetic architecture [8].

Our research group previously established three GC cell lines from tumor samples of individuals from Northern Brazil. ACP02 cell line was established from a diffuse-type GC, and ACP03 and AGP01 were from an intestinal-type GC. These cell lines exhibited a composite karyotype with several clonal chromosomal alterations. All these cell lines presented chromosome 8 trisomy—where MYC oncogene is located—and deletion of chromosome arm 17p, which

includes the *TP53* tumor suppressor locus. Moreover, chromosome 17 (chr17) trisomy in ACP03 and AGP01 cell lines was detected [12].

Here, we analyzed the number of *MYC*, *TP53*, and chr17 copies in 6th (short-duration culture), 12th (long-duration culture), 60th and 85th passages of ACP02, ACP03 and AGP01 cell lines, and in their parental primary tumors. We aim to evaluate whether these gene/chromosomal alterations occur in cell lines and in their tumor counterpart, as well as whether multiple passage growth leads to a difference in the frequency of these alterations.

2. Materials and Methods

FISH was performed on recently made slides from methanol/acetic acid fixed cells of four passages (6th, 12th, 60th, and 85th) of ACP02, ACP03, and AGP01 cell lines, as previously described [13]. FISH was also applied on nuclei isolated from parental primary tumors as previously reported [14]. Tumor samples were obtained from João de Barros Barreto University Hospital (HUJBB) in Pará State, Brazil.

To determine *MYC* gene copy number, cells were hybridized with a rhodamine-labeled probe (Chromotrax, USA) for *MYC* gene region (8q24.1-q24.2). To determine the chromosome 17 and *TP53* copy numbers, cells were hybridized using a dual-color direct labeled probe (Qbiogene, USA) specific for chr17 α -satellite and for *TP53* gene region, and labeled with fluorescein and rhodamine, respectively. Nuclei were counterstained with DAPI/antifade (Chemicon, USA). Fluorescence was detected using an Olympus BX41 fluorescence microscope with DAPI/FITC/TRICT filters (Olympus, Japan), and signals were analyzed using FISHView of Applied Spectral Imaging image analysis system (ASI Ldt., Israel). For each cell line or tumor, 200 interphase nuclei were analyzed and scored using the criteria of Hopman et al. [15]. To avoid misinterpretation due to technical error, gastric mucosal tissue (nonneoplastic) and normal lymphocyte nuclei were used as control.

For statistical analysis, the *MYC*, *TP53*, or chr17 copy numbers were compared among cell lines using Kruskal-Wallis nonparametric test followed by Games-Howell posthoc test. Friedman test followed by Wilcoxon posthoc test with Bonferroni correction were used to evaluate differences among primary tumor and their cell line passages. In all analyses, the confidence interval was 95%, and *P* values less than .05 were considered significant.

3. Results

3.1. *MYC*. Two signals for *MYC* probe were observed in 99.5% of peripheral blood lymphocytes and in 97% of normal gastric cells (Figure 1(a)). Table 1 shows the frequency of *MYC* signals in cell lines and parental tumors. In primary tumor samples, three *MYC* signals were the most frequent alteration, ranging from 39%–45% of cells (Figure 1(b)). In the 6th and 12th passages, 3 *MYC* signals were the most frequent alteration (about 40%) followed by 4 signals (about 28%). In the 60th passage of cell lines, 3 and 4 *MYC* signals

were commonly observed. In the 85th passage, the most frequent alteration was the presence of 4 signals for *MYC* probe, ranging from 33.5%–42% of cells. Five or more *MYC* copies by cells were also observed in all cell lines and parental tumors. High amplification of *MYC* was detected as clonal alteration mainly in cell lines (Figure 1(c)).

Statistical analysis revealed that the frequency of cells with high *MYC* amplification was significantly different among ACP02, ACP03, and AGP01 cell lines ($\chi^2 = 9.206$, *df* = 2, *P* = .01, by Kruskal-Wallis test). The Games-Howell posthoc analyses demonstrated that the ACP02, cell line, and parental tumor, presented a lower frequency of high *MYC* amplification cells than AGP01 (*P* = .019) and ACP03 (*P* = .014).

Concerning the *MYC* signal frequency during culture process, we observed that the frequency of cells with 2 ($\chi^2 = 10.933$, *df* = 4, *P* = .027, by Friedman test), 4 ($\chi^2 = 10.667$, *df* = 4, *P* = .031, by Friedman Test), 5 or more ($\chi^2 = 11.467$, *df* = 4, *P* = .022, by Friedman test), and high amplification ($\chi^2 = 11.429$, *df* = 4, *P* = .022, by Friedman test) *MYC* copies were significantly different among parental tumor and their passages. However, the posthoc analysis by Wilcoxon test with Bonferroni correction did not reveal any significant difference, probably due to the gradual alterations among passages (Figures 2(a), 2(b), 2(c), 2(d)).

3.2. *Chr17/TP53*. Two signals for chr17 and *TP53* were observed in about 97% of control cells (Figure 1(d)). Table 2 shows the frequency of chr17/*TP53* signals in cell lines from the 6th, 12th, 60th, and 85th passages and tumor samples.

The frequency of cells with 2 signals for chr17 and 2 signals for *TP53* was significantly different among ACP02, ACP03, and AGP01 cell lines ($\chi^2 = 6$, *df* = 2, *P* = .05, by Kruskal-Wallis test). The Games-Howell posthoc analyses demonstrated that the ACP02, cell line, and parental tumor presented a higher number of this cell type than AGP01. ACP02 also presented a higher frequency of cells with two copies of chr17 than AGP01 (*P* = .003, by Games-Howell posthoc analysis) and ACP03 (*P* = .009, by Games-Howell posthoc analysis).

The frequency of cells with 2/1 ($\chi^2 = 10.839$, *df* = 2, *P* = .004, by Kruskal-Wallis test), 2/3 ($\chi^2 = 11.423$, *df* = 2, *P* = .003, by Kruskal-Wallis test), and 3/3 ($\chi^2 = 10.691$, *df* = 2, *P* = .005, by Kruskal-Wallis test) copies of chr17/*TP53* was significantly different among cell lines. The Games-Howell posthoc analyses demonstrated that the ACP02 presented a higher frequency of cells with 2 copies of chr17 and loss of *TP53* than AGP01 (*P* = .001) and ACP03 (*P* = .001). In ACP02, the most common alteration observed was the loss of one copy of *TP53* (Figure 1(e)).

Only ACP03 and AGP01 presented clonal chr17 trisomy with two or three copies of *TP53*. Thus, the Games-Howell posthoc analysis among cell lines also demonstrated that AGP01 and ACP03 presented a higher frequency of cells with chr17 trisomy with 2 *TP53* copies than ACP02 (*P* = .035 and *P* = .15, resp.; Figure 1(f)). AGP01 also presented a higher frequency of cells with chr17 trisomy and 3 *TP53* copies than ACP02 (*P* = .013).




FIGURE 1: Fluorescence *in situ* hybridization assay. (a) Interphase nuclei presenting two *MYC* signals from normal gastric mucosa; (b) interphase nuclei presenting 2–5 *MYC* signals from ACP02 parental primary tumor; (c) interphase nuclei presenting *MYC* signal number alterations, including high amplification, from the 85th passage of AGP01 cell line; (d) interphase and metaphase cells presenting two copies of chr17/*TP53* from lymphocytes control, with the green spots representing the 17 centromere probe and the red representing the *TP53* gene probe; (e) interphase nuclei presenting two signals of chr17 and two or one *TP53* signal(s) from ACP02 parental primary tumor; (f) interphase nuclei presenting three signals for chr17 and two *TP53* signals from the 85th passage of ACP03 cell line.

TABLE 1: FISH analysis of MYC copy number in gastric cancer cell lines, in their parental primary tumors and in control samples.

		Nuclei exhibiting MYC signals, no. (%) ^a					
		1 signal	2 signals	3 signals	4 signals	≥5 signals	HA
ACP02	Parental primary tumor	0 (0)	57 (28.5)	78 (39)	57 (28.5)	8 (4)	0 (0)
	6th passage	1 (0.5)	40 (20)	84 (42)	62 (31)	13 (6.5)	0 (0)
	12th passage	0 (0)	34 (17)	88 (44)	63 (31.5)	15 (7.5)	0 (0)
	60th passage	0 (0)	6 (3)	83 (41.5)	79 (39.5)	24 (12.5)	7 (3.5)
	85th passage	2 (1)	8 (4)	65 (32.5)	84 (42)	30 (15)	11 (5.5)
ACP03	Parental primary tumor	0 (0)	39 (19.5)	84 (42)	41 (20.5)	23 (11.5)	13 (6.5)
	6th passage	0 (0)	33 (16.5)	89 (44.5)	40 (20)	24 (12)	14 (7)
	12th passage	1 (0.5)	19 (9.5)	85 (42.5)	51 (25.5)	29 (14.5)	15 (7.5)
	60th passage	1 (0.5)	8 (4)	71 (35.5)	63 (31.5)	39 (19.5)	18 (9)
	85th passage	0 (0)	6 (3)	47 (23.5)	69 (34.5)	49 (24.5)	29 (14.5)
AGP01	Parental primary tumor	0 (0)	47 (23.5)	90 (45)	37 (18.5)	17 (8.5)	9 (4.5)
	6th passage	4 (2)	12 (6)	69 (34.5)	59 (29.5)	36 (18)	20 (10)
	12th passage	1 (0.5)	13 (6.5)	70 (35)	56 (28)	33 (16.5)	27 (13.5)
	60th passage	0 (0)	2 (1)	64 (32)	63 (31.5)	41 (20.5)	30 (15)
	85th passage	1 (0.5)	1 (0.5)	45 (22.5)	67 (33.5)	49 (24.5)	37 (18.5)
Control	Normal stomach tissue	4 (2)	194 (97)	2 (1)	0 (0)	0 (0)	0 (0)
	Lymphocytes	1 (0.5)	199 (99.5)	0 (0)	0 (0)	0 (0)	0 (0)

^aThe FISH analysis was performed on 200 nuclei. HA: high amplification.

TABLE 2: FISH analysis of chr17/TP53 copy number in gastric cancer cell lines, in their parental primary tumors and in control samples.

		Nuclei exhibiting chr17/TP53 signals, no. (%) ^a						
		1/0 signal	1/1 signals	2/1 signals	2/2 signals	2/3 signals	3/2 signals	3/3 signals
ACP02	Parental primary tumor	3 (1.5)	4 (2)	63 (31.5)	130 (65)	0 (0)	0 (0)	0 (0)
	6th passage	2 (1)	4 (2)	62 (31)	132 (66)	0 (0)	0 (0)	0 (0)
	12th passage	0 (0)	7 (3.5)	73 (36.5)	120 (60)	0 (0)	0 (0)	0 (0)
	60th passage	1 (0.5)	10 (5)	84 (42)	104 (52)	1 (0.5)	0 (0)	0 (0)
	85th passage	2 (1)	25 (12.5)	102 (51)	69 (34.5)	1 (0.5)	0 (0)	1 (0.5)
ACP03	Parental primary tumor	2 (1)	14 (7)	17 (8.5)	100 (50)	0 (0)	54 (27)	13 (6.5)
	6th passage	3 (1.5)	15 (7.5)	14 (7)	86 (43)	3 (1.5)	47 (23.5)	32 (16)
	12th passage	4 (2)	8 (4)	9 (4.5)	75 (37.5)	4 (2)	55 (27.5)	45 (22.5)
	60th passage	1 (0.5)	1 (0.5)	2 (1)	21 (10.5)	2 (1)	70 (35)	103 (51.5)
	85th passage	3 (1.5)	0 (0)	5 (2.5)	6 (3)	5 (2.5)	121 (60.5)	60 (30)
AGP01	Parental primary tumor	6 (3)	29 (14.5)	7 (3.5)	116 (58)	4 (2)	12 (6)	26 (13)
	6th passage	5 (2.5)	12 (6)	4 (2)	36 (18)	0 (0)	31 (15.5)	112 (56)
	12th passage	0 (0)	9 (4.5)	3 (1.5)	35 (17.5)	6 (3)	37 (18.5)	110 (55)
	60th passage	4 (2)	4 (2)	0 (0)	30 (15)	5 (2.5)	36 (18)	121 (60.5)
	85th passage	3 (1.5)	7 (3.5)	0 (0)	23 (11.5)	3 (1.5)	70 (35)	94 (47)
Control	Normal stomach tissue	0 (0)	4 (2)	1 (0.5)	193 (96.5)	0 (0)	0 (0)	2 (1)
	Lymphocytes	0 (0)	3 (1.5)	1 (0.5)	195 (97.5)	1 (0.5)	0 (0)	0 (0)

^aThe FISH analysis was performed on 200 nuclei.

Concerning the chr17 and TP53 alterations during culture process, we observed that the frequency of cells with two copies of chr17/TP53 ($\chi^2 = 11.467$, df = 4, P = .022, by Friedman test), two chr17 copies ($\chi^2 = 10.373$, df = 4, P = .035, by Friedman test), and chr17 trisomy ($\chi^2 = 10.4$, df = 4, P = .034, by Friedman test) were significantly different among parental tumor and their passages. However, the posthoc analysis by Wilcoxon test with Bonferroni correction

did not reveal any significant difference, probably due to the gradual alterations among passages (Figures 2(e), 2(f), 2(g), 2(h)).

4. Discussion

Fluorescence *in situ* hybridization (FISH) assay allows rapid detection of numerical genetic aberrations in interphase




FIGURE 2: Continued.




FIGURE 2: Distribution of cells according to (a) *MYC* signals in AGP01 parental tumor and cell line passages; (b) *MYC* signals in ACP02 parental tumor and cell line passages; (c) *MYC* signals in ACP03 parental tumor and cell line passages; (d) mean of *MYC* signals of AGP01, ACP02, and ACP03 parental tumor and cell line passages; (e) *TP53*/chr17 signals in AGP01 parental tumor and cell line passages; (f) *TP53*/chr17 signals in ACP02 parental tumor and cell line passages; (g) *TP53*/chr17 signals in ACP03 parental tumor and cell line passages; (h) mean of *TP53*/chr17 signals of AGP01, ACP02, and ACP03 parental tumor and cell line passages.

nuclei in tumor cells. FISH assay should be used to evaluate cell-to-cell heterogeneity in gene or loci copy number and detect small subpopulations of genetically aberrant cells [16]. Using FISH assay, our research group previously reported several frequent aneusomies in GC samples and cell lines from individuals of Northern Brazil, which suggests a genomic instability [7, 12, 13, 17–20]. Molecular cytogenetic studies have shown that gains at 3q, 7p, 7q, 8q, 13q, 17q, 20p, and 20q and losses at 4q, 9p, 17p, and 18q are recurrent chromosomal alterations in GC. (For a review, see [21].)

Our research group has observed that chr8 trisomy, where *MYC* is located, is present in almost all gastric tumors and cell lines from our population by conventional and molecular cytogenetic analyses [7, 12, 13, 17, 19, 20, 22, 23]. We have previously described that ACP02, ACP03, and AGP01 at the 60th passage presented chr8 trisomy, as well as tetrasomy. In these cell lines, more than 5 signals of chr8 were observed in less than 5% of cells [12]. However, *MYC* copy number seems to be higher than the number of chr8 copies in our studies [19, 20, 23]. High *MYC* amplification has frequently been observed in primary tumors from our population, and we have also previously reported that *MYC* can be inserted into other chromosomes. The higher frequency of *MYC* high amplification in ACP03 and AGP01, originated from intestinal-type GC, than ACP02, originated from a diffuse-type GC, agrees with our previous observation in primary GC. Our group had observed that clonal high amplification of *MYC* is less frequent in diffuse-type than intestinal-type primary GC [19, 20, 23].

Thus, the presence of three or more copies of *MYC*, including gene high amplification, in all samples of the present study corroborates our previous observations in

primary GC. Moreover, the frequency of *MYC* gain in advanced GC observed by FISH seems to be higher in our population than in East Asia, which ranges from 15.5% to 48% of cases [6, 24, 25]. *MYC* amplification has been suggested as the main mechanism for its deregulation in GC (see review [26]).

Concerning *TP53*/chr17 copies, we observed that ACP02, cell line, and its parental tumor, presented cells with two copies of chr17 and loss of one copy of *TP53* more frequently than ACP03 and AGP01. This finding corroborates our previous study using dual-color FISH for chr17/*TP53* in primary tumor samples, in which we observed that the frequency of cells with two chr17 and one *TP53* signals was higher in the diffuse-type than in the intestinal-type GC [27].

We also observed that only ACP03 and AGP01 cells and parental tumors presented chr17 trisomy as clonal alteration, in agreement with the karyotype of these cell lines at 60th passage [12]. Although primary tumors of individuals from Northern Brazil present clonal chr17 trisomy or monosomy by FISH analysis [27], chr17 aneusomy is not the most frequent alteration within primary tumors of our population [7, 22, 28].

Moreover, we detected *TP53* loss in all cell lines and primary tumors. *TP53* somatic alteration is described in about 50% of human cancers, including GC [29]. Deletion of chromosome arm 17p was also observed in ACP02, ACP03, and AGP01 by conventional cytogenetic analysis [12]. In our population, *TP53* deletion was previously observed in all analyzed primary tumor samples, despite Laurén's histopathologic types; therefore, corroborating the present study [27].

Although we did not observe any significant difference among parental tumors and their cell line passages after posthoc analysis, we were able to observe that the number of *MYC* signals is significantly higher in cell lines than primary tumors. We also observed a reduction in the number of nuclei with two signals for chr17/*TP53* when we compared GC cell lines with their parental tumors, which reflects an increase of aneusomy cells.

Tumor samples are usually composed of a heterogeneous clonal population which can include nonneoplastic cells. The increased frequency of cells with *MYC* gain, *TP53* loss, and chr17 trisomy in cell lines may be due to the selection of a subpopulation of cancer cells during the cell line establishment. Normal cells can divide only a limited number of times *in vitro*, because of replicative senescence. However, some tumor cells can become immortal and, therefore, they do not undergo senescence when cultured *in vitro* [30]. According to the Hayflick limit, the maximum number of passages that a normal cell attains before senescence is about 50 [31]. Here, we evaluated GC cell lines in the 60th and in 85th passages, which select cells with genomic alterations that are essential for cell survival and proliferation *in vitro*.

A meta-analysis of the studies using comparative genomic hybridization assay to evaluate chromosomal alterations in cancer cell lines and primary tumors demonstrated that, on average, the relatively large-scale copy number genetic aberrations seen in cell lines *in vitro* accurately reflect their parent histology [8]. In this meta-analysis study, it was also reported that *MYC* oncogene amplification seems to be more frequent in cell lines in several histologies, indicating that the deregulation of this gene may be acquired as part of cell immortalization or that their occurrence is selected when tumors are chosen for transformation. Therefore, we suggest that, in our GC cell lines, cells with *MYC* amplification are selected during the long culture process.

5. Conclusion

Our findings reveal that ACP02, ACP03, and AGP01 cell lines retain *in vitro* the genetic alterations presented in their parental primary tumors. Thus, these findings suggest that these cell lines are an interesting model to study GC biology as well as to evaluate new anticancer strategies.

Acknowledgments

This paper was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; MACS and RRB) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; MFL and DQC).

References

- [1] L. Ottini, M. Falchetti, R. Lupi et al., "Patterns of genomic instability in gastric cancer: clinical implications and perspectives," *Annals of Oncology*, vol. 17, no. 7, pp. vii97–vii102, 2006.
- [2] D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, "Global cancer statistics, 2002," *Ca-A Cancer Journal for Clinicians*, vol. 55, no. 2, pp. 74–108, 2005.
- [3] A. D. Ferti-Passantonopoulou, A. D. Panani, J. D. Vlachos, and S. A. Raptis, "Common cytogenetic findings in gastric cancer," *Cancer Genetics and Cytogenetics*, vol. 24, no. 1, pp. 63–73, 1987.
- [4] J. C. Xia, S. Lu, J. S. Geng, S. B. Fu, P. Li, and Q. Z. Liu, "Direct chromosome analysis of ten primary gastric cancers," *Cancer Genetics and Cytogenetics*, vol. 102, no. 1, pp. 88–90, 1998.
- [5] H. Ochi, H. O. Douglass, and A. A. Sandberg, "Cytogenetic studies in primary gastric cancer," *Cancer Genetics and Cytogenetics*, vol. 22, no. 4, pp. 295–307, 1986.
- [6] Y. Kitayama, H. Igarashi, and H. Sugimura, "Different vulnerability among chromosomes to numerical instability in gastric carcinogenesis: stage-dependent analysis by FISH with the use of microwave irradiation," *Clinical Cancer Research*, vol. 6, no. 8, pp. 3139–3146, 2000.
- [7] P. P. Assumpcao, G. Ishak, E. S. Chen et al., "Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence *in situ* hybridization in individuals from northern Brazil with gastric adenocarcinoma," *Cancer Genetics and Cytogenetics*, vol. 169, no. 1, pp. 45–49, 2006.
- [8] J. Greshock, K. Nathanson, A. M. Martin et al., "Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization," *Cancer Research*, vol. 67, no. 8, pp. 3594–3600, 2007.
- [9] Y. Jin, H. Zhang, S. W. Tsao et al., "Cytogenetic and molecular genetic characterization of immortalized human ovarian surface epithelial cell lines: consistent loss of chromosome 13 and amplification of chromosome 20," *Gynecologic Oncology*, vol. 92, no. 1, pp. 183–191, 2004.
- [10] S. B. Ratsch, Q. Gao, S. Srinivasan, D. E. Wazer, and V. Band, "Multiple genetic changes are required for efficient immortalization of different subtypes of normal human mammary epithelial cells," *Radiation Research*, vol. 155, no. 1, part 2, pp. 143–150, 2001.
- [11] L. F. Meisner, S. Q. Wu, B. J. Christian, and C. A. Reznikoff, "Cytogenetic instability with balanced chromosome changes in an SV40 transformed human uroepithelial cell line," *Cancer Research*, vol. 48, no. 11, pp. 3215–3220, 1988.
- [12] M. F. Leal, J. L. Martins do Nascimento, C. E. A. da Silva et al., "Establishment and conventional cytogenetic characterization of three gastric cancer cell lines," *Cancer Genetics and Cytogenetics*, vol. 195, no. 1, pp. 85–91, 2009.
- [13] A. Costa Guimaraes, L. Goncalves Quintana, M. Ferreira Leal et al., "Aneuploidy of chromosome 8 detected by fluorescence *in situ* hybridisation in ACP01 cell line gastric adenocarcinoma," *Clinical and Experimental Medicine*, vol. 6, no. 3, pp. 129–133, 2006.
- [14] M. I. Stamouli, A. D. Ferti, A. D. Panani et al., "Application of multiplex fluorescence *in situ* hybridization in the cytogenetic analysis of primary gastric carcinoma," *Cancer Genetics and Cytogenetics*, vol. 135, no. 1, pp. 23–27, 2002.
- [15] A. H. N. Hopman, F. C. S. Ramaekers, A. K. Raap et al., "In *situ* hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors," *Histochemistry*, vol. 89, no. 4, pp. 307–316, 1988.
- [16] A. Kallioniemi, T. Visakorpi, R. Karhu, D. Pinkel, and O. P. Kallioniemi, "Gene copy number analysis by fluorescence *in situ* hybridization and comparative genomic hybridization," *Methods*, vol. 9, no. 1, pp. 113–121, 1996.
- [17] E. M. Lima, J. D. Rissino, M. L. Harada et al., "Conventional cytogenetic characterization of a new cell line, ACP01, established from a primary human gastric tumor," *Brazilian Journal of Medical and Biological Research*, vol. 37, no. 12, pp. 1831–1838, 2004.

- [18] A. C. Guimaraes, E. M. Lima, A. S. Khayat et al., "Interrelationships among chromosome aneuploidy, promoter hypermethylation, and protein expression of the CDKN2A gene in individuals from northern Brazil with gastric adenocarcinoma," *Cancer Genetics and Cytogenetics*, vol. 179, no. 1, pp. 45–51, 2007.
- [19] D. Q. Calcagno, M. F. Leal, A. D. Seabra et al., "Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma," *World Journal of Gastroenterology*, vol. 12, no. 38, pp. 6207–6211, 2006.
- [20] D. Queiroz Calcagno, M. Ferreira Leal, S. Satomi Takeno et al., "Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma," *Anticancer Research*, vol. 25, no. 6 B, pp. 4069–4074, 2005.
- [21] A. D. Panani, "Cytogenetic and molecular aspects of gastric cancer: clinical implications," *Cancer Letters*, vol. 266, no. 2, pp. 99–115, 2008.
- [22] R. Burbano, P. P. Assumpcao, M. Ferreira Leal et al., "C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil," *Anticancer Research*, vol. 26, no. 4 B, pp. 2909–2914, 2006.
- [23] D. Q. Calcagno, A. C. Guimaraes, M. F. Leal et al., "MYC insertions in diffuse-type gastric adenocarcinoma," *Anticancer Research*, vol. 29, no. 7, pp. 2479–2483, 2009.
- [24] S. H. Koo, K. C. Kwon, S. Y. Shin et al., "Genetic alterations of gastric cancer: comparative genomic hybridization and fluorescence in situ hybridization studies," *Cancer Genetics and Cytogenetics*, vol. 117, no. 2, pp. 97–103, 2000.
- [25] T. Hara, A. Ooi, M. Kobayashi, M. Mai, K. Yanagihara, and I. Nakanishi, "Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization," *Laboratory Investigation*, vol. 78, no. 9, pp. 1143–1153, 1998.
- [26] D. Q. Calcagno, M. F. Leal, P. P. Assumpcao, M. D. A. C. Smith, and R. R. Burbano, "MYC and gastric adenocarcinoma carcinogenesis," *World Journal of Gastroenterology*, vol. 14, no. 39, pp. 5962–5968, 2008.
- [27] A. S. Khayat, A. C. Guimaraes, D. Q. Calcagno et al., "Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma," *BMC Gastroenterology*, vol. 9, article 55, 2009.
- [28] S. Satomi Takeno, M. F. Leal, L. C. Frias Lisboa et al., "Genomic alterations in diffuse-type gastric cancer as shown by high-resolution comparative genomic hybridization," *Cancer Genetics and Cytogenetics*, vol. 190, no. 1, pp. 1–7, 2009.
- [29] K. Szymanska and P. Hainaut, "TP53 and mutations in human cancer," *Acta Biochimica Polonica*, vol. 50, no. 1, pp. 231–238, 2003.
- [30] R. R. Reddel, "The role of senescence and immortalization in carcinogenesis," *Carcinogenesis*, vol. 21, no. 3, pp. 477–484, 2000.
- [31] H. Rubin, "Promise and problems in relating cellular senescence in vitro to aging in vivo," *Archives of Gerontology and Geriatrics*, vol. 34, no. 3, pp. 275–286, 2002.



**The Scientific
World Journal**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Gastroenterology
Research and Practice**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**MEDIATORS
of
INFLAMMATION**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Journal of
Diabetes Research**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



Disease Markers

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**Journal of
Immunology Research**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



PPAR Research

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**International Journal of
Endocrinology**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**BioMed
Research International**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**Journal of
Ophthalmology**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**Stem Cells
International**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**eCAM
Evidence-Based
Complementary and
Alternative Medicine**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**Journal of
Obesity**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**Journal of
Oncology**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Computational and
Mathematical Methods
in Medicine**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**Behavioural
Neurology**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014




**Parkinson's
Disease**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**AIDS
Research and Treatment**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014



**Oxidative Medicine and
Cellular Longevity**

Hindawi Publishing Corporation
<http://www.hindawi.com>
Volume 2014